T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
Niels J M VerstegenRuth R HagenChristine KreherLisan H KuijperJet van den DijsselThomas AshhurstLaura Y L KummerVirginia Palomares CabezaMaurice SteenhuisMariël C DuurlandRivka de JonghC Ellen van der SchootVeronique A L KonijnErik MulKatherine KedzierskaKoos P J van DamEileen W StalmanLaura BoekelGertjan WolbinkSander W TasJoep KillesteinTheo RispensLuuk WieskeTaco W KuijpersFilip EftimovZoé Léonie Elise van KempenS Marieke van HamAnja Ten BrinkeCarolien E van de Sandtnull nullPublished in: Journal of neurology, neurosurgery, and psychiatry (2024)
These findings highlight the importance of optimising treatment regimens when scheduling SARS-CoV-2 vaccination for OCR-treated patients with MS to maximise their humoral and cellular immune responses. This study provides valuable insights for optimising vaccination strategies in OCR-treated patients with MS, including the identification of CD38 and HLA-DR as potential markers to explore vaccine efficacy in non-seroconverting OCR-treated patients with MS.